If you have been reading about obesity research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Nuclear fission === Einsteinium has a high rate of nuclear fission that results in a low critical mass. This mass is 9.89 kilograms for a bare sphere of 254Es, and can be lowered to 2.9 kg by adding a 30-centimeter-thick steel neutron reflector, or even to 2.26 kg with a 20-cm-thick reflector made of water. However, even this small critical mass far exceeds the total amount of einsteinium isolated so far, especially of the rare 254Es.
This article incorporates text from a free content work. Licensed under CC BY-SA IGO 3.0 (license statement/permission). Text taken from World Food and Agriculture – Statistical Yearbook 2023, FAO, FAO.
A seminal work of traditional Chinese medicine was the Huangdi neijing (Yellow Emperor's Inner Canon) compiled between the 3rd and 2nd centuries BC (i.e. originating in the Warring States period), which viewed the human body, its organs and tissues through the lens of the metaphysical five phases and yin and yang, and stated a belief in two circulatory channels of qi vital energy. In surgery, Han dynasty era Chinese texts offered practical advice for certain procedures such as clinical lancing of abscesses. The first known physician in China to describe the use anesthesia for patients undergoing surgery was the Eastern Han physician Hua Tuo (d. 208 AD), who utilized his knowledge of Chinese herbology based in the Huangdi neijing to create an ointment that healed surgical wounds within a month. One of his surgical procedures was the removal of a dead fetus from the womb of a woman whom he diagnosed and cured of her ailments.
== Facilities and subsidiaries == The BMC is headquartered in Lobatse. Its facilities consist of an integrated complex which includes an abattoir, canning, tanning and by-products plants. A throughput of 8000 cattle and 500 small stock are handled on a daily basis. The BMC also operates two branch abattoirs, one in Maun and the other in Francistown, with respective capacities of 100 cattle per day and 400 cattle and 150 small stock per day. Along with its core business, the BMC owns transport companies in Botswana. On an international scale, it also owns marketing subsidiaries in European countries including the United Kingdom, Germany and the Netherlands, and cold storage facilities in the UK and South Africa. It also owns an insurance company in the Cayman Islands.
Sources: en.wikipedia.org
== Distribution and habitat == R. hasseltii can only be found on several locations in Kerinci Seblat National Park, Sumatra, Indonesia, and Peninsular Malaysia, including Taman Negara and Temengor Forest Reserve. The type locality of the species in what is now West Sumatra, where it was first described, had gone extinct as a result of local plantation expansion. This plant is entirely dependent on host species from the genus Tetrastigma.
NADH-ferredoxin oxidoreductase reduced nicotinamide adenine dinucleotide-ferredoxin NADH-ferredoxin reductase NADH flavodoxin oxidoreductase NADH2-ferredoxin oxidoreductase Other enzymes in the family include:
Brec Bassinger as Courtney Whitmore / Stargirl:A high school student from Los Angeles who finds a powerful weapon, the Cosmic Staff, and becomes the superheroine Stargirl. As Stargirl, she also becomes the leader of the second incarnation of the Justice Society of America (JSA). In preparation for the role, Bassinger did not look at the character's previous portrayals by Britt Irvin on Smallville and Sarah Grey on Legends of Tomorrow because they were depicted as "older, more mature version[s]" of Stargirl. Bassinger added that the series follows the comic Stars and S.T.R.I.P.E. more "in that she's young, high school, naive", which she wanted to bring that into her version of Stargirl. Maizie Smith portrays a five-year old Courtney. Yvette Monreal as Yolanda Montez / Wildcat II:A once popular student at Blue Valley High until a scandal made her an outcast and a disgrace to her Catholic parents. A skilled boxer, she becomes one of Courtney's friends and a member of the new JSA as the new Wildcat. Anjelika Washington as Beth Chapel / Doctor Mid-Nite II: A social reject and nerd who becomes one of Courtney's friends and a member of the new JSA as the new Doctor Mid-Nite. Cameron Gellman as Rick Tyler / Hourman II:A high school delinquent with anger issues and the son of the original Hourman whose parents were killed in a staged car accident when he was seven. He becomes one of Courtney's friends and a member of the new JSA as the new Hourman. Boston Pierce portrays a 7-year-old Rick. Trae Romano as Mike Dugan: Pat Dugan's son and Courtney's stepbrother.
== Aspergillus flavus == Aspergillus flavus is a fungus of the family Trichocomaceae with a worldwide distribution. The mold lives in soil, surviving off dead plant and animal matter, but spreads through the air via airborne conidia. This fungus grows in long branched hyphae and is capable of surviving on numerous food sources including corn and peanuts. Aspergillus species commonly cause disease in humans and other animals either through mycotoxicosis (poisoning) or through fungal infections. Aflatoxin B1 is a key contributor to the toxicity of foods contaminated with the fungus. A. flavus is capable of parasitizing many host species. In humans, Aspergillus flavus along with Aspergillus fumigatus are common agents of fungal infections referred to as aspergillosis. These species primarily infect the lungs of immune-compromised patients, but A. flavus infections of the skin, eye, and other organs also occur. Unlike many mold species, Aspergillus flavus prefers hot and dry conditions; its optimal growth at 37 °C (99 °F) contributes to its pathogenicity in humans. Species that do not grow well at body temperature cannot typically infect humans.
=== Water === In 1998, perchlorate was included in the U.S. EPA Contaminant Candidate List, primarily due to its detection in California drinking water. In 2002, the EPA completed its draft toxicological review of perchlorate and proposed a reference dose of 0.00003 milligrams per kilogram per day (mg/kg/day) based primarily on studies that identified neurodevelopmental deficits in rat pups. These deficits were linked to maternal exposure to perchlorate. In 2003, a federal district court in California found that the Comprehensive Environmental Response, Compensation and Liability Act applied, because perchlorate is ignitable, and therefore was a "characteristic" hazardous waste. Subsequently, the U.S. National Research Council of the National Academy of Sciences (NAS) reviewed the health implications of perchlorate, and in 2005 proposed a much higher reference dose of 0.0007 mg/kg/day based primarily on a 2002 study by Greer et al. During that study, 37 adult human subjects were split into four exposure groups exposed to 0.007 (7 subjects), 0.02 (10 subjects), 0.1 (10 subjects), and 0.5 (10 subjects) mg/kg/day. Significant decreases in iodide uptake were found in the three highest exposure groups. Iodide uptake was not significantly reduced in the lowest exposed group, but four of the seven subjects in this group experienced inhibited iodide uptake. In 2005, the RfD proposed by NAS was accepted by EPA and added to its integrated risk information system (IRIS).
Sources: en.wikipedia.org
=== Inhibition of glucose oxidation === In 1948, Knox et al. proposed the idea that inhibition of glucose oxidation is a major factor in the bacteriocidal nature of chlorine solutions. They proposed that the active agent or agents diffuse across the cytoplasmic membrane to inactivate key sulfhydryl-containing enzymes in the glycolytic pathway. This group was also the first to note that chlorine solutions (HClO) inhibit sulfhydryl enzymes. Later studies have shown that, at bacteriocidal levels, the cytosol components do not react with HClO. In agreement with this, McFeters and Camper found that aldolase, an enzyme that Knox et al. proposes would be inactivated, was unaffected by HClO in vivo. It has been further shown that loss of sulfhydryls does not correlate with inactivation. That leaves the question concerning what causes inhibition of glucose oxidation. The discovery that HClO blocks induction of β-galactosidase by added lactose led to a possible answer to this question. The uptake of radiolabeled substrates by both ATP hydrolysis and proton co-transport may be blocked by exposure to HClO preceding loss of viability. From this observation, it proposed that HClO blocks uptake of nutrients by inactivating transport proteins. The question of loss of glucose oxidation has been further explored in terms of loss of respiration. Venkobachar et al. found that succinic dehydrogenase was inhibited in vitro by HClO, which led to the investigation of the possibility that disruption of electron transport could be the cause of bacterial inactivation. Albrich et al.
This was announced after the BBC had experimented with 8K during the London Olympics. On January 27, 2013, Asahi Shimbun reported that 4K Ultra HD satellite broadcasts would start in Japan with the 2014 FIFA World Cup. Japan's Ministry of Internal Affairs and Communications decided on this move to stimulate demand for 4K Ultra HD TVs. On February 21, 2013, Sony announced that the PlayStation 4 would support 4K resolution output for photos and videos but wouldn't render games at that resolution. On March 26, 2013, the Advanced Television Systems Committee (ATSC) announced a call for proposals for the ATSC 3.0 physical layer that specifies support for 3840 × 2160 resolution at 60 fps. On 11 April 2013, Bulb TV created by Canadian entrepreneur Evan Kosiner announced a 4K linear channel and VOD content to cable and satellite companies in North America. The channel planned to be licensed by the Canadian Radio-Television and Telecommunications Commission to provide educational content. On April 19, 2013, SES announced the first Ultra HD transmission using the High Efficiency Video Coding(HEVC) standard. The transmission had a resolution of 3840 × 2160 and a bit rate of 20 Mbit/s. On May 9, 2013, NHK and Mitsubishi Electric announced that they had jointly developed the first HEVC encoder for 8K Ultra HD TV, which is also called Super Hi-Vision (SHV). The HEVC encoder supports the Main 10 profile at Level 6.1 allowing it to encode 10 bpc video with a resolution of 7680 × 4320 at 60 fps.
==== Asbestos fibers ==== Many common building materials (especially those manufactured in the United States before 1976) contain asbestos, such as some floor tiles, ceiling tiles, shingles, fireproofing, heating systems, pipe wrap, taping muds, mastics, and other insulation materials. Normally, significant releases of asbestos fiber do not occur unless the building materials are disturbed, such as by cutting, sanding, drilling, or building remodeling. Removal of asbestos-containing materials is not always optimal because the fibers can be spread into the air during the removal process. A management program for intact asbestos-containing materials is often recommended instead. When asbestos-containing material is damaged or disintegrates, microscopic fibers are dispersed into the air. Inhalation of asbestos fibers over long exposure times is associated with increased incidence of lung cancer, mesothelioma, and asbestosis. The risk of lung cancer from inhaling asbestos fibers is significantly greater for smokers. The symptoms of disease do not usually appear until about 20 to 30 years after the first exposure to asbestos. Although all asbestos is hazardous, products that are friable, e.g. sprayed coatings and insulation, pose a significantly higher hazard as they are more likely to release fibers to the air.
== Leadership == On 2 April 2025, President Bola Ahmed Tinubu dissolved the board of NNPC Limited and appointed Bayo Ojulari as the new group chief executive officer(GCEO). Ahmadu Musa Kida was appointed the new non-executive chairman, replacing Chief Pius Akinyelure. Subsequently, on 22 May 2025, President Bola Ahmed Tinubu officially inaugurated the new board and executive leadership at a ceremony held at Aso Rock Villa, Abuja. The 11-member board comprises representatives from Nigeria’s six geopolitical zones, including:
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.